September 13, 5PM EDT – Registration Required

Why U.S biotechs are coming to Australia and how they are saving up to a year in regulatory timelines and considerable costs.

Learn how U.S. biotechs expedite their early phase clinical research program. With no IND required to start your clinical program in Australia, biotechs are able to save up to a year in regulatory timelines and considerable costs.

Avance Clinical and Australia tick all the boxes for early phase trials:

  • Plus up to 43.5% cash rebate on clinical trial spend.
  • Our clients are currently experiencing a 3-week IRB/EC turnaround due to the supportive regulatory and clinical environment, and Avance Clinical’s experience
  • Avance Clinical data is accepted by all the major regulatory authorities including the FDA and EMA.
  • With almost 50% of adults vaccinated, Australia has prioritized clinical research as an essential service which supports Avance Clinical’s biotech clients, clinical sites, and patients seeking access to therapies.

Yvonne Lungershausen, CEO, Avance Clinical 

Yvonne began her career in academic “bench” research with Adelaide University and CSIRO. Yvonne then moved into clinical trials research at a dedicated Phase I unit where she was one of the first in Australia to test a new chemical entity in healthy volunteers, giving rise to what is now a strong Phase 1 sector in Australia. Yvonne also spent time in the biotech world as Clinical Development Manager then moved into senior Contract Research Organisation (CRO) roles. With 25+ years of clinical trial experience gained across most therapeutic areas, Yvonne brings a deep understanding of all phases of the drug development process. With a passion for exceeding client expectations, Yvonne is highly regarded within the industry for her expertise and ability to solve complex clinical trial issues.

In 2009 Yvonne Lungershausen became a Founding Member of CPR Pharma Services (CPR) as it spun out from the University of South Australia. As a key member of the CPR Senior Management Team she was responsible for the clinical operations side of the business. In January 2019, CPR Pharma Services split into two separate service companies, analytical services (Agilex Biolabs) and clinical services (Avance Clinical). Yvonne was appointed as CEO of Avance Clinical and has since rapidly built the company into Australia’s leading CRO for biotechs – attracting innovative biotech clients from USA, EU and Asia and winning awards for quality and service.

September 14, 9AM EDT – Registration Required

Company Valuation for Fundraising – Trends and Tools

Valuation is a key aspect of fundraising. An average value assumption for each company in a specific financing stage just does not do it anymore. For entrepreneurs, as for investors, its important to understand the value drivers of a company. We are looking at the financing trends of the last years, discuss dos and don’ts when speaking with investors and look at how to value a life science company with no revenues.

Patrik Frei, Founder & CEO, Venture Valuation AG, Switzerland

Dr. Patrik Frei is founder and CEO of Venture Valuation AG, Switzerland. He started the company in 1999 when he noticed a need for independent valuation services in high growth industries during a collaboration with Novartis Venture Fund, which became his first client. Since then he has been involved in over 450 valuations for investors as well as biotech, Pharma and medtech companies. Patrik graduated from the Business University of St. Gallen and completed his PhD thesis (”Assessment and valuation of high growth companies”) at the Swiss Federal Institute of Technology, EPFL Lausanne. Patrik was a board member and one of the original founders of Ineo, a holding company of the Swiss dental implant VC-backed firm Thommen Medical and also the Chairman of Ophthalmopharma, a Swiss based biotech ophthalmology company, where he successfully out-licensed a portfolio of 4 products. Furthermore, Patrik was member of the board of Aventron AG (AVEN:Berne) a publicly quoted cleantech company, which raised over USD 160m during his time as board member. Patrik’s articles have been published in a number of scientific journals including “Nature Biotechnology”, “Chimia” and other business publications (“Starting a Business in the Life Sciences: From Idea to Market” and “Building Biotechnology: Starting, Managing, and Understanding Biotechnology Companies”). He has also lectured at Seoul National University, South Korea, EPFL Lausanne, University of St. Gallen and gives regular workshops on valuation.

Gergely Ivanyi, PharmD, Business Analyst, Venture Valuation

Gergely holds a PharmD degree from Semmelweis University (Budapest, Hungary) and an MSc in Bioentrepreneurship degree from Karolinska Institutet (Stockholm, Sweden). He worked over two years in business operations at startups in Sweden and Germany, and at a pharmaceutical distributor in Hungary. Before joining Venture Valuation, Gergely interned at a Swedish mutual fund, where he acquired the Investment Foundations certification by the CFA Institute and supported portfolio managers in the assessment of investment opportunities. Pursuing his interest in analyzing innovative life science companies, Gergely joined Venture Valuation in February 2020 as a Business Analyst. His primary responsibilities are: working on the global Biotechgate database, creating industry trend reports and financing deal summaries, as well as working on valuation projects.

September 14, 11AM EDT – Registration Required

Beyond Banking: Finding the Right Financial Partner for You

When your startup firm gains traction, you will inevitably need a bank that can add value and understand your distinct early-stage entrepreneurial needs. There are an array of financial institutions that have programs in the life science market to aid and guide early-stage entrepreneurs to set up the right financial packages. First Republic Bank is a leader in the early-stage life science market with decades of experience and dedicated teams that provide support to scientist entrepreneurs. In this fireside chat, we discuss the programs and services available for startups and how to engage and take advantage of the FRB offerings to help your business grow.

Nishta Rao, Managing Director, Life Science, First Republic Bank

Nishta is currently Managing Director at First Republic Bank where she is responsible for the growth and expansion of the Bank’s Life Science vertical. Prior to this, Nishta was Managing Director, BioLabs@NYULangone where she supported the translation of technologies into commercially viable products and therapies. In addition Nishta has also launched and led Princeton Innovation Center BioLabs (PICb). Nishta served as Senior Director of Scientific Operations at Kadmon, a biotech startup based in New York City that focuses on discovery, development, and commercialization of small molecules and biologics. Nishta, a molecular biologist by training, has scientific experience both in academia and industry. She has worked at Mt. Sinai Innovation Partners, the technology transfer office at Mt. Sinai as a Business Development Analyst evaluating technologies and developing partnerships aimed towards commercialization of new technologies. Nishta also serves as a mentor to several startup companies in the Life Science and Healthcare space.

Dennis Ford, Founder & CEO, Creator of RESI Conference Series, Life Science Nation

Dennis Ford is an entrepreneur and author with expertise in sales, marketing, and business development. He has spent most of his career finding, vetting and launching a myriad of technology-based companies. Over the last decade, he has worked extensively with global alternative investors and is deeply interested in getting funding for high-growth early-stage technologies. He is a big proponent of using profiling and matching technology to find that all-important business fit in the marketing and selling process. In today’s context Dennis can connect early stage life science companies with 10 categories of global partners thus making the finding of capital and distribution channels very efficient.

Dennis created the Redefining Early Stage Investments conference series to facilitate an interactive ongoing dialog between buyers and sellers in the life science arena. Before LSN, Dennis was the President and CEO of a company that improved the way hedge fund and private equity fund managers raised capital and marketed their funds to investors.

Ford is the author of The Peddler’s Prerogative and The Life Science Executive’s Fundraising Manifesto, two well-received sales and marketing books.

September 14, 1PM EDT – Registration Required

UCSF Innovation Ventures and Entrepreneurship Program

UCSF’s Innovation Ventures is the group that helps translate UCSF innovation from the lab to the market. It includes Tech Transfer, Partnering/Strategic Alliances, two internal funds to de-risk science for a startup or licensing, and an Entrepreneurship Program that has facilitated the start of 40 companies raising $750MM in 5 years. The Entrepreneurship Program is offering a global online course, Entrepreneurship for Life Science/Healthcare: Master Class Direct from Silicon Valley, that in one year generated over 200 alumni from 13 countries and 4 continents. Hear about this important effort at UCSF and the global class.

Stephanie Marrus, Managing Director, Entrepreneurship, UCSF Innovation Ventures

Stephanie Marrus is Managing Director, Entrepreneurship, UCSF Innovation Ventures. She has facilitated the start of numerous companies based on UCSF science and medicine. She is a key node in the Silicon Valley entrepreneurship ecosystem and has built industry relationships with investors, serial entrepreneurs, accelerators, founders, attorneys, consultants that benefit UCSF startups. She currently heads an open program that delivers online life science/healthcare entrepreneurship training globally.

She has been affiliated with entrepreneurship programs at UC Berkeley and Stanford, has presented on five continents and works with the US State Department.

Prior to joining UCSF, she held C-Suite business roles in biotechnology companies. She has been CEO, COO and VP Corporate Development for public and private firms, led partnering and M&A transactions, headed Corporate Development, Strategy, Marketing, Communications and Investor Relations.

She holds an MBA from the Wharton School, University of Pennsylvania and an MA from Columbia University.

September 14, 3PM EDT – Registration Required

Fundraising Bootcamp

The Fundraising Boot Camp provides a top-to-bottom master class on outbound global fundraising. Topics to be covered include the Changing Investor Landscape, New Categories of Life Science Investors, Debunking the Top 10 Old Myths in Fundraising, Planning & Infrastructure for an Outbound Fundraising Campaign, Building Your Brand Through Consistent Messaging and Key Components of Fundraising Marketing Collateral. It will bring you step-by-step through the processes of positioning, marketing collateral, website creation, branding & messaging, and how to reach out to a list of global investors.

Greg Mannix, VP of International Business Development, Life Science Nation

Greg Mannix is Vice President of International Business Development at Life Science Nation. After graduating from the University of California, he moved to Europe where he began a career in the life sciences and obtained a Master’s degree from IE Business School in Madrid. He has extensive experience in sales and marketing management in the medical devices field. He has worked extensively in Europe, North America and Latin America and he speaks English, Spanish and French. Greg’s role at LSN is to provide international early-stage companies with the tools and strategies to successfully fundraise and to facilitate cross-border investments, licensing and M&A transactions.

Karen Deyo, Director of Investor Research, Israel BD, Strategic Projects, Life Science Nation

Karen Deyo is the Director of Investor Research, Israel BD, Strategic Projects at Life Science Nation. In addition to her role curating the LSN Investor Platform, she is actively involved in Israel BD, utilizing her professional and personal connections to connect LSN to the Israeli life sciences startup community. She has also been involved in evaluating companies for the Innovation and Pitch Challenges for LSN’s RESI conference series, evaluating several hundred companies since joining LSN. Additionally, Karen manages LSN’s Partnering Platform across all its conferences, and is involved in LSN’s Branding and Messaging services, helping emerging companies refine their marketing collateral to aid in successful fundraising campaigns. Karen has a Masters of Engineering in Biomedical Engineering as well as a Certificate in Graduate Business Study from Worcester Polytechnic Institute and a Bachelor of Science degree in Engineering with a concentration in Bioengineering from Olin College of Engineering.

September 15, 11AM EDT – Registration Required

Negotiating Term Sheets: What’s Best for the Company and What’s Best for You?

This interactive workshop, organized and led by McDermott Will & Emery, will provide wisdom to early-stage CEOs and management on the latest trends in term sheets, with a focus on founder and management equity opportunities. The workshop will cover common issues of concern to entrepreneurs (valuation/dilution, liquidation preference, board makeup, protective provisions, anti-dilution). Experts from the legal, investment and entrepreneurial community will discuss the interplay of financing milestones in the term sheet discussion.

David Hendren, Managing Director, Augmentum Ventures

David Hendren has extensive experience launching, financing, and building successful ventures from incubation to exit, with particular expertise in healthcare, biomedical technology, digital health, and related technology and service areas. He has deep knowledge and broad perspective from 25+ years in leadership roles on virtually all sides of the table, including VC, entrepreneur, CEO, board member/chair, advisor, consultant, and counsel. David has led, co-invested and executed deals with leading firms and strategics, with exits including IPO, M&A, and technology licensing transactions. In operating, board, and advisory roles, David has been central to identifying opportunity, building teams, formulating strategy, securing capital, developing business and strategic alliances, and driving successful exits to harvest value for stakeholders.

Mark Mihanovic, Partner, McDermott Will & Emery

Mark J. Mihanovic, head of the Firm’s California Corporate group and head of the Emerging Companies/Venture Capital group, focuses his practice primarily in the areas of corporate finance and mergers and acquisitions. He represents companies in a broad range of industries, with a particular emphasis on technology, life science and health care companies. Mark serves as corporate liaison partner in the Firm’s strategic alliance with MWE China Law Offices based in Shanghai. Mark serves as lead counsel on behalf of issuers and underwriters in public offerings and private placements (including private investments in public equities (PIPEs)) of equity and debt securities. He handles stock and asset acquisitions, divestitures, mergers, proxy fights and joint ventures and has had primary oversight responsibility for the regional and worldwide acquisition programs of multiple clients. Mark represents early-stage companies in connection with formation and organizational issues and venture capital and other financings and has also represented investors in complex venture capital transactions involving equity and debt. Mark has substantial experience advising corporate boards of directors and management regarding fiduciary duties (including in connection with potential change in control transactions and consideration of “poison pill” stockholders rights plans) and corporate governance issues. He assists publicly traded companies with their Securities and Exchange Commission filings and other securities compliance matters. He also advises investment banks on securities compliance issues and in acting as financial adviser and delivering fairness opinions in the context of acquisitions and restructurings.

Brian M. Gordon, Partner, McDermott Will & Emery – Atlanta

Brian M. Gordon represents venture-backed technology companies in acquisitions, financing transactions, the negotiation of credit facilities, corporate governance, employment and equity compensation matters and the resolution of day-to-day legal issues.

Brian also has significant experience representing private equity funds in the acquisitions and disposition of portfolio companies, in both control and non-control transactions. He counsels strategic buyers and sellers in M&A transactions. He also represents restaurants and retail groups in private equity and acquisition transactions.

Nancy Briefs, President & CEO, AltrixBio, Inc.

Strategic business leader with extensive experience creating value, driving strategy and launching product commercialization in diverse life science companies. Deep general management and fundraising expertise having raised over $500 M in equity including IPO. Innovative, collaborative and entrepreneurial, strong communicator and tenacious. Energized by turning innovation into commercial reality, working with creative scientists, and communicating value to partners and investors.

September 15, 1PM EDT – Registration Required

Financing Scientific Instrumentation as a Startup Company

Over the last several years, a record number of exciting life sciences start-ups have come online. Most of these start-up companies need scientific instrumentation to support their research. But when funds are limited, how can these companies get the instrumentation needed to hit their growth milestones? Workshop will kick off with an overview of the leasing market for start-ups. Expert panel will share their own experiences going through the leasing process and offer valuable lessons learned.

  • Darren Platt, President, Demetrix
  • Bryan Leavitt, Managing Partner, Fountainhead Investment Partner
  • Chad Kobold, Director of Business, Development, Bold View Capital

September 15, 3PM EDT – Registration Required

How to Evaluate Your Banking Partner Workshop

Life Science companies need more from a bank than just accounts and transactions. The right banking partner brings a mix of excellent service, industry expertise, and the ability to help companies grow. Join Nishta Rao of First Republic Bank to hear what companies should be looking for in a sound banking partner.

Nishta Rao, Managing Director, Life Science, First Republic Bank

Nishta is currently Managing Director at First Republic Bank where she is responsible for the growth and expansion of the Bank’s Life Science vertical. Prior to this, Nishta was Managing Director, BioLabs@NYULangone where she supported the translation of technologies into commercially viable products and therapies. In addition Nishta has also launched and led Princeton Innovation Center BioLabs (PICb). Nishta served as Senior Director of Scientific Operations at Kadmon, a biotech startup based in New York City that focuses on discovery, development, and commercialization of small molecules and biologics. Nishta, a molecular biologist by training, has scientific experience both in academia and industry. She has worked at Mt. Sinai Innovation Partners, the technology transfer office at Mt. Sinai as a Business Development Analyst evaluating technologies and developing partnerships aimed towards commercialization of new technologies. Nishta also serves as a mentor to several startup companies in the Life Science and Healthcare space.

Host a Webinar to Highlight Services

Workshops are sponsored webinars designed to educate leaders of fundraising companies on elements of the early-stage landscape often overlooked, which can include patents, recruitment, intellectual property, insurance, financial management, and so much more. Service providers interested in sponsoring and hosting a workshop can contact the RESI team to learn more.

Contact Us